Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.57 |
| ▸ | GABRP | O00591 | 2/20 | 0.57 |
| ▸ | GABRD | O14764 | 2/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.57 |
| ▸ | GABRE | P78334 | 2/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.57 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.57 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.57 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CCKBR | P32239 | 10/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589100 | 1.00 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL7818438 | 0.98 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9039929 | 0.85 | GABRP (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9040366 | 0.82 | TP53 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10331866 | 0.76 | CA12 (0.46) | KDM4EALDH1A1HPGDCCKBRCCKAR | |
| SCHEMBL10332105 | 0.76 | CA12 (0.46) | KDM4EALDH1A1HPGDCCKBRCCKAR | |
| Hydrochloric Acid SCHEMBL7819286 | 0.75 | GABRP (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6302389 | 0.73 | CCKBR (0.51) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2923672 | 0.73 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1835654 | 0.73 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | claimed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
| US-7528249-B2 | Cyclic malonamides as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-06-22 | — | — | US | disclosed |
| US-7053081-B2 | Cyclic malonamides as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | OLSON RICHARD E (US) | 2005-01-13 | — | — | US | disclosed |
| US-6759404-B2 | INHIBITING GAMMA-SECRETASE ACTIVITY; TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID PRODUCTION, SUCH AS ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | APP, BACE1, APBA1 | GABRA1 2066/4885GABRG2 2574/4885GABRB3 1677/4885 |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | APP, BACE1, APH1A | GABRA1 2995/4885GABRG2 3638/4885GABRB3 2957/4885 |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | GABRA1 2159/4885GABRG2 2713/4885GABRB3 1917/4885 |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | APP, BACE1, APBA1 | GABRA1 2159/4885GABRG2 2713/4885GABRB3 1917/4885 |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | GABRA1 2118/4885GABRG2 2664/4885GABRB3 1770/4885 |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | APP, BACE1, APH1A | GABRA1 1464/4885GABRG2 1700/4885GABRB3 1691/4885 |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | APP, APBA1, APH1A | GABRA1 2246/4885GABRG2 3113/4885GABRB3 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.